Table 1.

RCTs assessing the effects of modafinil (see text).

Reference	Population	Intervention/comparison	Significance
	248 children, aged 6–13 years	Modafinil 300 mg v placebo	ADHD-RS-IV (teacher-related) total score: mean changes from baseline represented graphically; P = 0.006
	Modafinil 300 mg, 50 children; modafinil 100/200 mg, 48 children; modafinil 200/100 mg, 49 children; modafinil 200/200 mg, 50 children; placebo, 51 children		ADHD-RS-IV (clinician-related): mean changes from baseline represented graphically; P = 0.006
			Conners' ADHD/DSM-IV scale (total score): mean changes from baseline represented graphically; P = 0.01
		Modafinil 100/200 mg v placebo	Conners' ADHD/DSM-IV scale (total score): mean changes from baseline represented graphically; P = 0.01No significant difference compared with placebo on teacher- or clinician-related version ADHD-RS-IV, mean changes from baseline presented graphically: reported as not significant; P values not reported
		Modafinil 200/100 mg v placebo	ADHD-RS-IV (teacher-related) total score: mean changes from baseline represented graphically; P = 0.03
			ADHD-RS-IV (clinician-related): mean changes from baseline represented graphically; reported as not significant; P value not reported
			Conners' ADHD rating scale ADHD index: mean changes from baseline represented graphically reported as not significant; P value not reported
		Modafinil 200/200 mg v placebo	ADHD-RS-IV (teacher-related): mean changes from baseline represented graphically; reported as not significant; P value not reported
			ADHD-RS-IV (clinician-related): mean changes from baseline represented graphically; P = 0.01